Looking for up-to-date information on biological medicines? You can find it here!
We’ve linked resources from multiple providers into one place so it’s easy for you to find what you need.
Humira to Amgevita - Experience from over the ditch
Hover over the timeline to find the different chapters in this video.
This recorded webinar covers the introduction of the adalimumab biosimilar Amgevita in New Zealand, and what it means for primary care. Specialist Dr David Liew shares his experiences of changing patients from biologics to biosimilars in Australia, and Andrea Copeland provides some local context.
This resource will not be available after 30 June 2024 as He Ako Hiringa is shutting down. If your organisation would like to host this resource please contact admin@akohiringa.co.nz
Dr David Liew is a consultant rheumatologist and clinical pharmacologist based at Austin Health, Melbourne. His research interests include immune-related adverse events from checkpoint inhibitors for cancer, polymyalgia rheumatica, value-based rational prescribing, and pharmaceutical drug safety.
Andrea Copeland is the education lead for He Ako Hiringa. She is a registered pharmacist and is passionate about health equity, public health, continuous quality improvement and clinical education.
This video is a recording of the live webinar hosted by He Ako Hiringa on 15 March 2022 and is intended for a health professional audience.
The video has been edited for clarity.
Timeline
- 00:00 - 03:14 Introduction
- 03:14 - 36:24 Dr David Liew: Biosimilars in rheumatology, the Australian experience
- 36:24 - 44:00 Andrea Copeland: Local context
- 44:00 - 1:16:35 Q&A and closing
Resources mentioned in this webinar
• Our biological medicines resource hub contains content from multiple providers.
• Episodes 1 and 2 of our Legendary Conversations podcast cover initiating new medicines, and minimising the nocebo effect.
• The Amgevita website supports patients & clinicians and includes an 0800 number to connect you with nurses experienced with using Amgevita.
• The Pharmac website contains prescribing, dispensing and consumer information about adalimumab.
Professional college endorsements
This activity has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 1.5 CME credits for continuing professional development purposes (1 credit per learning hour). To claim your CPD credits, log in to your Te Whanake dashboard and record these activities under the appropriate learning category.
This activity has been endorsed by the PSNZ as suitable for inclusion in a pharmacist’s CE records for CPD purposes.
Related Articles
